| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/27/2007 | US7183307 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/27/2007 | US7183304 Heterocyclic compounds and methods of use |
| 02/27/2007 | US7183297 For therapy of rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome |
| 02/27/2007 | US7183295 Compound for treatment of lipemic agents, antiinflammatory agents and treatment of diabetes |
| 02/27/2007 | US7183290 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 02/27/2007 | US7183277 Alpha-((aryl or heteroaryl)ureido or carbamoyloxy)-N-heteroaryl amides; blood-coagulation factor Xa and VIIa inhibitors; synergistic mixtures with other antitumor agents or anticoagulants |
| 02/27/2007 | US7183264 Such as ethyl-1-(9-((4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxy-methyl)oxolan-2-yl)-6 -aminopurin-2-yl)pyrazole-4-carboxylate; adenosine receptors (A2A); for stimulating mammalian coronary vasodilatation for therapy and imaging the heart |
| 02/27/2007 | US7183260 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 02/27/2007 | US7183078 Nucleotide sequences coding mammalian histamine H4 receptor protein for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders |
| 02/27/2007 | US7183075 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 02/27/2007 | US7183063 Can be used in screening for agents which act as antagonists to MCP-1, MIP-1 alpha and/or RANTES |
| 02/27/2007 | US7182971 Comprising 15-70% by weight of diglycerides in which less than 15% by weight of constitutive fatty acids are omega 3 type unsaturated fatty acids, and 30-85% by weight of a triglyceride in which at least 15% by weight of constitutive fatty acids are omega 3 type; for oral medicinal formulations and foods |
| 02/27/2007 | US7182953 Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| 02/27/2007 | CA2432798C Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 02/27/2007 | CA2425849C Angiostatic steroids |
| 02/27/2007 | CA2168517C Substituted thiophenylsulfonylureas and -thioureas processes for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 02/23/2007 | CA2513027A1 Method of inhibiting vascular permeability |
| 02/22/2007 | WO2007022173A2 Crystalline forms fenoldopam mesylate |
| 02/22/2007 | WO2007022089A2 Methods to identify therapeutic agents useful for treating and preventing atherosclerosis by counteracting the effect of cholesterol ozonation products |
| 02/22/2007 | WO2007021682A1 Method of use of deacetylase inhibitors |
| 02/22/2007 | WO2007021210A1 Method for treating diseases caused by vascular diseases |
| 02/22/2007 | WO2007021034A1 Scavenger of harmful active oxygen and/or free radical in living body |
| 02/22/2007 | WO2007020917A1 Agent for enhancing and prolonging utrophin production and processed food comprising the same |
| 02/22/2007 | WO2007020888A1 Brain/neuronal cell-protecting agent, and therapeutic agent for sleep disorder |
| 02/22/2007 | WO2007020533A2 Process for the preparation of losartan potassium |
| 02/22/2007 | WO2007020521A1 Pyridoyrazinones as pde-5 inhibitors |
| 02/22/2007 | WO2007020421A1 Crystalline and amorphous sodium atorvastatin |
| 02/22/2007 | WO2007020413A1 Crystalline and amorphous sodium atorvastatin |
| 02/22/2007 | WO2007020348A1 Proanthocyanidin tannin composition, production method thereof and use of same |
| 02/22/2007 | WO2007020286A2 Method of using potassium channel inhibiting compounds |
| 02/22/2007 | WO2007020009A1 New crystalline form of perindopril erbumine |
| 02/22/2007 | WO2006105214A3 Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
| 02/22/2007 | WO2006081431A3 Compounds for treating inflammatory and demyelinating diseases |
| 02/22/2007 | WO2006069202A3 Compositions comprising anti-igf-i receptor antibodies and methods for obtaining said antibodies |
| 02/22/2007 | WO2006002119A3 Kinase inhibitors for treating cancers |
| 02/22/2007 | US20070043220 {2-Methyl-4-[3-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid; diabetes mellitus, Metabolic Syndrome, atherosclerosis, cardiovascular diseases,Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension |
| 02/22/2007 | US20070043119 Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
| 02/22/2007 | US20070043114 Nerve regeneration promoters |
| 02/22/2007 | US20070043105 Preventive for cerebal stroke recurrence |
| 02/22/2007 | US20070043095 have a good affinity for certain subtypes of somatostatin receptors and have useful pharmacological properties |
| 02/22/2007 | US20070043081 N-Cyclopropyl-N-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro-benzenesulfonamide; 2-(4-Chloro-phenyl)-N-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-methyl-acetamide; neurohormonal antagonists |
| 02/22/2007 | US20070043079 Heterocyclic compound containing nitrogen atom and use thereof |
| 02/22/2007 | US20070043069 3-Amino-3,4-dihydro-1,5-naphthyridin-2(1H)-one and its dihydrochloride; intermediates for producing naphthyridinylaminocarbonyl-substituted pyrrolothiopyrans and imidazolothiopyrans |
| 02/22/2007 | US20070043053 for treating p38 kinase-associated conditions like inflammatory disorders; improved dissolution rate and oral bioavailability; rheumatic diseases; skin disorders; multiple sclerosis; osteoporosis; Alzheimer's disease |
| 02/22/2007 | US20070043018 2"-Hydroxynicotianamine, process for producing the same and angiotensin converting enzyme inhibitor, hypotensive drug and health food |
| 02/22/2007 | US20070042965 Crystallized structure of type IV collagen NC1 domain hexamer |
| 02/22/2007 | US20070042964 Compositions and methods for modulating connexin hemichannels |
| 02/22/2007 | US20070042446 Drug screening; for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 02/22/2007 | US20070041996 Aromatase activating agent |
| 02/22/2007 | DE102005038831A1 New N-acylalkoxycarbonyl-piperidine derivatives, useful as CGRP antagonists, for treating e.g. headaches, cardiovascular disease, skin disorders, morphine tolerance, and inflammatory diseases such as osteoarthritis and allergic rhinitis |
| 02/22/2007 | DE10101522B4 Neue pharmazeutische Verwendung einer Kombination aus Ascorbat und mindestens einem Fibrinolysehemmer New pharmaceutical use a combination of ascorbate and at least one Fibrinolysehemmer |
| 02/22/2007 | CA2818921A1 Method of reducing the risk of adverse cardiovascular (cv) events associated with the administration of pharmaceutical agents which favor cv events |
| 02/22/2007 | CA2619769A1 Scavenger of in vivo harmful reactive oxygen species and/or free radicals |
| 02/22/2007 | CA2619486A1 Crystalline and amorphous sodium atorvastatin |
| 02/22/2007 | CA2619480A1 Method of using potassium channel inhibiting compounds |
| 02/22/2007 | CA2619040A1 Crystalline and amorphous sodium atorvastatin |
| 02/22/2007 | CA2618990A1 Methods to identify therapeutic agents useful for treating and preventing atherosclerosis by counteracting the effect of cholesterol ozonation products |
| 02/22/2007 | CA2618653A1 Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder |
| 02/22/2007 | CA2618516A1 New crystalline form of perindopril erbumine |
| 02/22/2007 | CA2617636A1 Use of histone deacetylase inhibitors for treating cardiac hypertrophy and heart failure |
| 02/22/2007 | CA2615636A1 Treatment of diseases by subcutaneous administration of a vegf antagonist |
| 02/22/2007 | CA2613465A1 Crystalline forms fenoldopam mesylate |
| 02/22/2007 | CA2608245A1 Process for the preparation of losartan potassium |
| 02/21/2007 | EP1754714A1 cyclic peptide derivatives as inhibitors of integrin alpha v beta 6 |
| 02/21/2007 | EP1754707A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 02/21/2007 | EP1754703A2 N-Heterocyclic derivatives as nos inhibitors |
| 02/21/2007 | EP1754475A1 Use of C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 02/21/2007 | EP1753746A2 Novel pyrrole derivatives with angiotensin ii antagonist activity |
| 02/21/2007 | EP1753738A1 Pyrrole compounds as inibitors of erk protein kinase, synthesis thereof and intermediates thereto |
| 02/21/2007 | EP1753720A1 Process for the preparation of perindopril and salts thereof |
| 02/21/2007 | EP1753456A2 Methods for treating conditions associated with masp-2 dependent complement activation |
| 02/21/2007 | EP1753429A1 Modulators of muscarinic receptors |
| 02/21/2007 | EP1753418A2 Compositions comprising nebivolol |
| 02/21/2007 | EP1529047B1 New purine derivatives |
| 02/21/2007 | EP1501508B1 Inhibitors of histone deacetylase |
| 02/21/2007 | EP1458690B1 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
| 02/21/2007 | EP1355905B1 Pyrazole compounds useful as protein kinase inhibitors |
| 02/21/2007 | EP1339428B1 Inhalation of nitric oxide |
| 02/21/2007 | EP1328546B1 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 02/21/2007 | EP1328254B1 Lipid formulations for target delivery |
| 02/21/2007 | EP1311482B1 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 02/21/2007 | EP1255749B1 Tyrosine derivatives with anti-leukotriene activity |
| 02/21/2007 | EP1231279B1 Process for producing tripeptides |
| 02/21/2007 | EP1224155B1 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 02/21/2007 | EP1140071B1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors |
| 02/21/2007 | EP1135374B9 Benzimidazole compounds that are vitronectin receptor antagonists |
| 02/21/2007 | EP1133474B1 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 02/21/2007 | CN1918128A Fused ring 4-oxopyrimidine derivative |
| 02/21/2007 | CN1918127A New cyclocompound having 4-pyridylalkylthio group to which sustituted or unsubstituted amino group is introduced |
| 02/21/2007 | CN1917899A Use of alkaline phosphatase for the detoxification of lps |
| 02/21/2007 | CN1917887A The use of o-atp for the treatment of diseases involving angiogenesis |
| 02/21/2007 | CN1917866A Use of treprostinil to treat and prevent ischemic lesions |
| 02/21/2007 | CN1917865A Combination of organic compounds |
| 02/21/2007 | CN1916028A Polysaccharide outside cyst of lactobacillus casei and crude product, prepartion method and application |
| 02/21/2007 | CN1916022A Gene correlative to cardiovascular pathology caused by diabetes, and usage |
| 02/21/2007 | CN1916021A Amido glycoside of sea pearl oyster, prepartion method, and usage |
| 02/21/2007 | CN1916014A Extractive of alfalfa, preparation method and usage |
| 02/21/2007 | CN1916013A Pharmaceutical compounds |
| 02/21/2007 | CN1915986A High purified tanshinone óÄA sodium sulfonate, fabricating method, and preparation |
| 02/21/2007 | CN1915981A 2-oxy-benzoxazinone derivatives for the treatment of obesity |